Sign in
Not yet taking people in SpainPhase 2/3

Cleminorexton versus placebo for narcolepsy and other long-term excessive sleepiness conditions

Tests cleminorexton against placebo for daytime sleepiness in adults with narcolepsy.

Key facts

Who runs it
Centessa Pharmaceuticals UK Limited
Where
Alzira, Barcelona, Madrid, and Vitoria, SpainSee the 9 sitesAlso in 7 other countries, 18 sites
Registry title
A Study to Investigate the Effects of Cleminorexton Compared with Placebo in the Treatment of Participants with Central Disorders of Hypersomnolence
Status
Not yet recruiting
Phase
Phase 2/3
People taking part
198 people, planned
Started
1 Oct 2026
Expected to end
1 Feb 2028
Type of study
Interventional
Record updated
13 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with narcolepsy type 1 or type 2 who have strong daytime sleepiness. It compares cleminorexton with placebo, a dummy treatment.

Age
18 Years and older
Sex
All sexes
Disease stage
A doctor diagnosed narcolepsy type 1 (with cataplexy) or type 2 (without cataplexy) within the past 10 years. Average time to fall asleep on a stay-awake test (MWT) must be < 21 minutes. People with type 1 must have ≥ 4 cataplexy episodes (sudden muscle weakness) per week over 14 days. They must fill in a diary on at least 11 of those 14 days.
Earlier treatment
People with type 1 must first stop medicines for cataplexy. Medicines for daytime sleepiness must be stopped first, such as stimulants, wake-promoting drugs, sodium oxybate or mixed-salt oxybate. Sleeping pills, including melatonin, are not allowed. Antidepressants and other medicines that affect cataplexy must stop at least 7 days before the sleep diary starts.
Biomarker or test result
People with type 1 need a positive test for the tissue type HLA DQB1*06:02. This can be from screening or an earlier test. People cannot join if a spinal fluid test showed orexin A > 110 pg/mL, where such a test exists.

Main reasons for not taking part

  • Another condition causing daytime sleepiness, such as untreated sleep apnea or a limb-movement index > 15
  • Serious heart, cancer, nervous system, mental health or other illness
  • Heart rhythm problems on ECG, or QTcF >450 msec in males or > 470 msec in females
  • Blood pressure or pulse outside set limits
  • Pregnancy, breastfeeding, or usual bedtime later than 1:00 AM

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • A physician documented diagnosis of NT1 according to International Classification of Sleep Disorders, 3rd edition, Text Revision edition (ICSD-3-TR) criteria within the past 10 years from informed consent
  • Positive test result for the human leukocyte antigen (HLA) genotype HLA DQB1*06:02 (either during Screening or based on a documented historical test result)
  • A mean sleep latency on the MWT (average of the first 4 trials) at Baseline of < 21 minutes
  • After washout of medications used for the treatment of cataplexy, must complete self-reported cataplexy questions in the diary for at least 11 days of the 14-day period prior to the Baseline visit and have ≥ 4 partial or complete episodes of cataplexy/week, averaged over 14 consecutive days prior to the Baseline visit
  • A physician documented diagnosis of NT2 according to ICSD-3-TR criteria within the past 10 years from informed consent
  • Mean sleep latency on the MWT (average of the first 4 trials) at Baseline of < 21 minutes

Who cannot take part

  • Use of any medications that could affect the evaluation of cataplexy (including antidepressants) within 7 days before the baseline sleep diary. Participants must have returned to baseline level of cataplexy by the time of the beginning of the cataplexy diary, in the opinion of the investigator. "
  • Use of any medications that could affect the evaluation of EDS (eg, medications that stimulate the central nervous system [CNS])
  • Any medical disorder other than NT1 or NT2, that is associated with excessive daytime sleepiness (EDS): evidence of untreated or inadequately treated moderate-to-severe sleep-disordered breathing and/or periodic limb-movement-arousal index > 15
  • Conditions related to the following: cardiac, malignancy, gastrointestinal, endocrine, neurologic, psychiatric, immunologic, other significant conditions or comorbidities that would make the participant unsuitable to be randomized and/or participate
  • Use of medications for EDS (including wake-promoting agents, stimulants, and sodium oxybate or mixed-salt oxybate). Certain washout periods apply (see Appendix 10.7 for full details)
  • Positive serum pregnancy test at Screening or Baseline, or is a pregnant, lactating/ female participant
  • QT interval using the Fridericia formula (QTcF) >450 msec for males or > 470 msec for females or evidence of clinically significant electrocardiogram (ECG) abnormality (eg, 2nd or 3rd degree atrioventricular block [known history of Mobitz Type I may be considered with approval from the Sponsor or designee], left bundle branch block [LBBB])
  • A cerebrospinal fluid (CSF) orexin A (OXA) > 110 pg/mL (if available)
  • Use of hypnotics (including melatonin)
  • Abnormalities at Screening or Baseline in blood pressure (BP, systolic BP > 140 mm Hg or < 90 mm Hg; diastolic BP > 90 mm Hg or < 50 mm Hg) or pulse rate (> 100 bpm or < 40 bpm)
  • Usual bedtime later than 1:00 AM (01:00)

Where in Spain

Also in 7 other countries, 18 sites

  • Hospital Universitario de La RiberaAlzira, SpainNot yet recruiting
  • Hospital Clinic de BarcelonaBarcelona, SpainNot yet recruiting
  • Hospital Universitari Vall d'HebronBarcelona, SpainNot yet recruiting
  • Hospital La Milagrosa S.A.Madrid, SpainNot yet recruiting
  • Hospital Nuestra Senora De AmericaMadrid, SpainNot yet recruiting
  • Hospital Pardo De Aravaca S.A.Madrid, SpainNot yet recruiting
  • Hospital Universitario HM SanchinarroMadrid, SpainNot yet recruiting
  • Hospital Universitario La PazMadrid, SpainNot yet recruiting
  • Hospital Universitario ArabaVitoria, SpainNot yet recruiting

About the trial

What the trial wants to find out

Evaluate the effect of cleminorexton versus placebo on EDS

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Randomized, Double-blind, 3-Arm Parallel Design Study to Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Cleminorexton Compared with Placebo in Participants with Central Disorders of Hypersomnolence
Plain-language title
Cleminorexton versus placebo for narcolepsy and other long-term excessive sleepiness conditionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 November 2026